Paper Details

  1. Home
  2. Paper Details

Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review.

Author: Poulin-BrièreAmélie, PozziSilvia, RezaeiEdris

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Antibody-based therapies are being investigated as potential treatments for Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease affecting motor neurons. This review summarizes 31 studies that investigated the efficacy of antibodies targeting both extracellular and intracellular proteins involved in ALS, including SOD1, TDP-43, and C9ORF72 repeat expansions. The potential benefits and limitations of these therapies are discussed.
Paper Details　
Original Abstract of the Article :
Amyotrophic Lateral Sclerosis (ALS) is a mid-life onset neurodegenerative disease that manifests its symptomatology with motor impairments and cognitive deficits overlapping with Frontotemporal Lobar Degeneration (FTLD). The etiology of ALS remains elusive, with various mechanisms and cellular targe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667723/

データ提供：米国国立医学図書館（NLM）

A New Frontier in ALS Treatment: Antibody-Based Interventions

Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease that presents a formidable challenge for healthcare professionals. This study reviews the growing field of antibody-based therapeutic interventions for ALS, exploring the potential of these approaches to target specific molecular pathways and cellular processes implicated in disease pathogenesis. The authors delve into the various antibody targets, ranging from extracellular molecules to intracellular pathogenic proteins, and discuss the potential and limitations of these therapeutic strategies.

Antibodies: A New Weapon in the Fight Against ALS

The review highlights the potential of antibody-based interventions to target both extracellular molecules and intracellular pathogenic proteins associated with ALS, offering a promising avenue for therapeutic development. The authors analyze various antibody targets, including SOD1, TDP-43, and C9ORF72 repeat expansions, and discuss their potential to modify disease progression. The review emphasizes the need for further research to optimize antibody-based interventions and ensure their safety and efficacy.

Hope for ALS Patients on the Horizon

This review provides a comprehensive overview of the evolving landscape of antibody-based therapies for ALS, highlighting the potential of this approach to address a complex and debilitating disease. The research offers hope for ALS patients and underscores the importance of ongoing research to advance the development of effective treatments for this devastating condition.

Dr.Camel's Conclusion

This study offers a glimpse into the promising future of antibody-based therapies for ALS. The review highlights the potential of these interventions to target specific molecular pathways and cellular processes implicated in disease pathogenesis. The findings provide a roadmap for future research and development, offering hope for ALS patients and their families.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-12-17
Further Info :

Pubmed ID

34912191

DOI: Digital Object Identifier

PMC8667723

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.